Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Renal microvascular injury occurs in most patients with diabetes, representing one of the main causes underlying chronic kidney disease development. We have previously published that overexpression of adaptor protein p66Shc is implicated in the loss of renal microvascular reactivity in rats with diabetic nephropathy (DN) induced by injection of streptozotocin (STZ). Since sulfur heteroarotinoid A2 (SHetA2) is known to interfere with p66Shc signaling, we tested whether SHetA2 would restore renal microvascular reactivity and mitigate kidney injury in our rat model of DN. Dahl salt sensitive wild-type (SS) and p66Shc knockout rats were used in a well-established rat model of DN, characterized by progressive proteinuria, hyperfiltration, and display of renal histological lesions. SHetA2 was either added acutely to isolated rat afferent arterioles or chronically administrated to rats during DN development. The ability of SHetA2 treatment to restore afferent arteriolar contraction in response to increased perfusion pressure or ATP was evaluated using the perfused juxtamedullary nephron preparation. The progression of renal damage was evaluated by measuring urinary protein excretion. Comparison of renal microvascular responses to perfusion pressure in p66Shc knockout rats and parental SS rats, in the presence and absence of acute preincubation with SHetA2, revealed ability of SHetA2 to restore renal microvascular reactivity in SS rats with little effect upon p66Shc knockouts. Moreover, chronic treatment with SHetA2 prevented loss of renal microvascular responses. Even though targeting p66Shc with SHetA2 restored renal afferent arteriolar reactivity caused by DN, it had limited effect upon a biomarker of renal injury. Thus, additional studies are necessary to develop SHetA2 for prevention and treatment of DN-induced kidney damage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12361120 | PMC |
| http://dx.doi.org/10.3389/fphys.2025.1620591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications.
Curr Opin Rheumatol
September 2025
Division of Rheumatology, Department of Internal Medicine.
Purpose Of Review: This review explores the evolving understanding of vascular dysfunction in systemic sclerosis (SSc), from early endothelial injury to clinical manifestations and emerging therapeutic strategies.
Recent Findings: Endothelial cell (EC) injury, senescence, and endothelial-to-mesenchymal transition are central to SSc vasculopathy. Single-cell and spatial omics have revealed distinct EC subtypes and dysregulated pathways, including interferon signaling and chromatin remodeling.
A novel treatment for diabetic nephropathy: Folate receptor-targeted delivery of TLR4 siRNA via functionalized PLGA nanoparticles in streptozotocin-induced diabetic murine models.
Nanomedicine
September 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China; Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, People's Republic of China; Key laboratory of nephropathy, The S
Diabetic kidney disease (DKD), a prominent microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD), was addressed through a novel nanotherapeutic approach. This study engineered folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles (FA-PLGA NPs) for the folate receptor (FR)-targeted delivery of Toll-like receptor 4 small interfering RNA (TLR4 siRNA) to treat diabetic nephropathy (DN). In a streptozotocin-induced DN murine model, administration of FA-PLGA NPs/TLR4 siRNA significantly mitigated renal injury compared to untreated DN controls.
View Article and Find Full Text PDFPrevalence and importance of coronary microvascular dysfunction in patients with heart failure and reduced or mildly reduced ejection fraction.
Open Heart
September 2025
Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden.
Aims: We investigated the prevalence of coronary microvascular dysfunction (CMD) and its association with severity of heart failure in patients with reduced or mildly reduced ejection fraction (HFrEF and HFmrEF).
Method: Patients with stable, symptomatic heart failure with left ventricular ejection fraction (LVEF) <50% were enrolled. Data collection included physical examination, blood samples, Kansas City Cardiomyopathy Questionnaire (KCCQ), carotid to femoral pulse wave velocity, echocardiography and adenosine-based transthoracic Doppler echocardiography to assess coronary flow reserve (CFR).
Artificial intelligence oculomics for systemic health and longevity medicine: 2025 and beyond.
Curr Opin Ophthalmol
September 2025
Singapore National Eye Center, Singapore Eye Research Institute.
Purpose Of Review: With the rise of 'oculomics' and the application of advanced artificial intelligence techniques in healthy ageing, retinal imaging, the only way we can directly visualize the microvascular circulation, is expanding beyond ophthalmology into broader systemic health monitoring. The purpose of this review is to summarize recent advances in this rapidly evolving field and assess the opportunities, challenges, and future directions of the use of oculomics in translating into real-world clinical use.
Recent Findings: Retinal imaging modalities, such as color fundus photography, optical coherence tomography (OCT), OCT angiography (OCTA), and wide-field imaging, are increasingly integrated with deep learning algorithms to detect, predict, and manage a broad spectrum of systemic diseases, including cardiovascular, cerebrovascular, renal, metabolic, and neurodegenerative disorders, as well as less commonly studied conditions.
Vascular Effects of SGLT2 Inhibitors: Evidence and Mechanisms.
Am J Physiol Cell Physiol
September 2025
Obesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM). However, robust clinical evidence has demonstrated that their therapeutic benefits extend beyond glycemic control. SGLT2i reduce hospitalization for heart failure (HF), slow the progression of chronic kidney disease (CKD), and provide cardiorenal protection even in individuals without diabetes but with cardiovascular disease.
View Article and Find Full Text PDF